Jazz Pharmaceuticals and Saniona Enter Exclusive Licensing Agreement for SAN2355 Development and Commercialization

Jazz Pharmaceuticals has entered into an exclusive licensing agreement with Saniona to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications. Saniona will receive a $42.5 million upfront payment and potential milestone payments, while Jazz will lead and fund further development, regulatory submissions, and global commercialization activities.

Title: Jazz Pharmaceuticals and Saniona Partner to Develop Epilepsy Treatment

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) have entered into an exclusive licensing agreement to develop and commercialize SAN2355, a preclinical asset designed to treat epilepsy and other potential indications. Under the terms of the agreement, Saniona will receive an upfront payment of $42.5 million, with potential milestone payments for development, regulatory, and sales achievements. Jazz Pharmaceuticals will lead and fund the further development, regulatory submissions, and global commercialization activities.

SAN2355 is a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator, designed to overcome the limitations of non-selective Kv7-targeting compounds. The asset is in preclinical development and has shown promise in epilepsy treatment. Jazz Pharmaceuticals, known for its expertise in epilepsy and neuroscience, will leverage its experience to advance SAN2355 through clinical trials and commercialization.

Saniona, a clinical-stage biopharmaceutical company, has a pipeline focused on neurological and psychiatric disorders. The company's CEO, Thomas Feldthus, expressed optimism about the collaboration, stating, "Our collaboration with Jazz leverages their leading position in epilepsy and their strong track record of rapidly advancing clinical development programs and effectively commercializing novel therapies in neuroscience, positioning SAN2355 as a promising option for epilepsy and neurological conditions."

Jazz Pharmaceuticals' executive vice president, global head of research and development, and chief medical officer, Dr. Robert Iannone, added, "SAN2355 is a unique and highly promising preclinical asset that has the potential to become a best-in-class Kv7 activator for the treatment of epilepsy. We are pleased to enter this exclusive agreement with Saniona to lead the SAN2355 clinical development program."

The licensing agreement includes significant milestone payments and tiered royalties based on future net sales of commercial products resulting from the development of SAN2355. Jazz Pharmaceuticals has a history of innovation and commercial success in the neuroscience field, and this partnership further expands its early-stage pipeline.

References:
[1] https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-enters-exclusive-licensing-agreement-with-saniona-to-develop-and-commercialize-san2355-302534545.html